



Poly Medicure Ltd.

POLYMED
Medical Devices

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate, Phase - III, New Delhi - 110020, INDIA
Tel : +91-11-26321838, 26321881, 26321899, 26321889, 26321893, Fax : +91-11-26321894, 26321839
E-mail : info@polymedicure.com Website : www.polymedicure.com
CIN : L40300DL1995PLC066923

Date: 09th November, 2016

Ref: PML/SEC/2016-17/

Scrip Code: - 531768

Scrip Code:- POLYMED

The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Subject: Outcome of the Board Meeting of the Company

Ref: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 09th November, 2016, at Crowne Plaza Hotels, Community Center, Okhla Phase-I, New Delhi - 110020, approved the following businesses:

- Un-Audited Financial Results (Standalone) for the quarter and half year ended on 30th September, 2016.
- declared interim dividend for the financial year 2016-17, of Re. 1.00/- (Rupee One Only) per Equity Share i.e. @20% (Twenty) on equity shares of Rs. 5.00/- each fully paid-up of the Company; and
- fixed the Record Date as 15th November, 2016 for the payment of Interim Dividend for the F.Y. 2016-17

The said interim dividend will be paid to the shareholders on or before 08th December, 2016.

We request you to take the above on record and the same be treated as the necessary compliance under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You,

Yours Sincerely

For Poly Medicure Limited


Avinash Chandra
Company Secretary



(Rs. In lacs)

	Particulars	Quarter ended			Half Year Ended		Year ended
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
		(Unaudited)			(Unaudited)		(Audited)
1	Income from operations						
a	Net sales / income from operations	10,474.51	10,249.33	10,091.38	20,723.84	19,672.83	39,539.68
	(Inclusive of excise duty) - refer note no. 3						
b	Other operating income	188.17	166.11	96.56	354.28	175.63	475.76
	Total income from operations (gross)	10,662.68	10,415.44	10,187.94	21,078.12	19,848.46	40,015.44
2	Expenses						
a	Cost of materials consumed	3,229.89	3,565.05	3,479.83	6,794.94	6,922.07	13,177.29
b	Purchases of stock-in-trade	136.05	171.90	168.06	307.95	311.83	676.13
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(165.45)	(253.93)	24.46	(419.38)	90.60	200.25
d	Excise Duty on sales	153.49	146.66	141.57	300.15	271.90	567.60
e	Employee benefits expense	2,015.52	1,989.14	1,715.94	4,004.66	3,287.00	6,899.23
f	Depreciation and amortisation expense	552.07	533.09	494.81	1,085.16	1,012.50	2,018.79
g	Other expenses	2,996.52	2,482.59	2,589.46	5,479.11	5,095.15	10,048.79
	Total expenses	8,918.09	8,634.50	8,614.13	17,552.59	16,991.05	33,588.08
3	Profit from operations before other income, finance costs and exceptional items (1-2)	1,744.59	1,780.94	1,573.81	3,525.53	2,857.41	6,427.36
4	Other income	219.61	203.20	299.08	422.81	470.25	838.50
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	1,964.20	1,984.14	1,872.89	3,948.34	3,327.66	7,265.86
6	Finance costs	160.13	187.63	153.26	347.76	352.75	778.24
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,804.07	1,796.51	1,719.63	3,600.58	2,974.91	6,487.62
8	Exceptional items	-	-	-	-	-	-
9	Profit from ordinary activities before tax (7 + 8)	1,804.07	1,796.51	1,719.63	3,600.58	2,974.91	6,487.62
10	Tax expense	561.47	530.13	458.42	1,091.60	738.32	1,756.87
11	Net Profit from ordinary activities after tax (9 - 10)	1,242.60	1,266.38	1,261.21	2,508.98	2,236.59	4,730.75
12	Extraordinary items	-	-	-	-	-	-
13	Net Profit for the period (11 + 12)	1,242.60	1,266.38	1,261.21	2,508.98	2,236.59	4,730.75
14	Paid-up equity share capital (Face Value of Rs. 5 each)	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67	2,205.67
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						20,177.89
16	Earnings per share (before extraordinary items) (Quarterly not annualised and yearly annualised) :						
	Basic (Rs.)	2.82	2.87	2.86	5.69	5.07	10.72
	Diluted (Rs.)	2.82	2.87	2.86	5.69	5.07	10.72

Statement of Assets and Liabilities

	Particulars	As at	
		30.09.2016	31.03.2016
		(Unaudited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	2,205.67	2,205.67
	(b) Reserves and surplus	22,166.59	20,177.89
	Sub-total - Shareholders' funds	24,372.26	22,383.56
2	Minority interest	-	-
3	Non-current liabilities		
	(a) Long-term borrowings	3,355.83	3,106.28
	(b) Deferred tax liabilities (net)	1,278.97	1,183.37
	(c) Other long-term liabilities	483.02	357.99
	(d) Long-term provisions	286.56	256.51
	Sub-total - Non-current liabilities	5,404.38	4,904.15
4	Current liabilities		
	(a) Short-term borrowings	2,859.03	3,039.38
	(b) Trade payables	2,925.38	2,957.53
	(c) Other current liabilities	4,415.45	3,797.33
	(d) Short-term provisions	883.70	503.08
	Sub-total - Current liabilities	11,083.56	10,297.32
	TOTAL - EQUITY AND LIABILITIES	40,860.20	37,585.03
B	ASSETS		
1	Non-current assets		

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th November, 2016 and have also been limited reviewed by Statutory Auditor of the Company.
- The Board of Directors of the company have declared interim Dividend of Rs. 1 per equity share having face value of Rs. 5 each
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- Revenue from operations for the quarter ended 30th September 2016 and for all comparable periods / year ended 31st March 2016 is grossed up with the amount of excise duty on sales and the same is being shown as part of expenditure in accordance with SEBI clarification dated 20th September 2016.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.



(a) Fixed assets	19,966.62	19,096.77
(b) Non-current investments	561.06	561.06
(c) Long-term loans and advances	1,572.30	1,290.91
(d) Other non-current assets	283.40	336.47
Sub-total - Non-current assets	22,383.38	21,285.21
2 Current assets		
(a) Inventories	4,925.49	4,058.25
(b) Trade receivables	8,996.85	8,029.07
(c) Cash and bank balances	2,348.59	2,147.87
(d) Short-term loans and advances	1,379.71	1,283.06
(e) Other current assets	826.18	781.57
Sub-total - Current assets	18,476.82	16,299.82
TOTAL - ASSETS	40,860.20	37,585.03

Place : New Delhi

Date : 09.11.2016

By order of the Board



Himanshu Baid

Managing Director



DOOGAR & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT

The Board of Directors

Poly Medicure Limited
232B, 3rd Floor, Okhla Industrial Estate,
Phase III, New Delhi – 110 020.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicure Limited (the 'Company') for the quarter ended September 30, 2016. This statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initiated by us for identification purposes. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the "Listing Regulations, 2015", including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place of Signature: New Delhi
Date: 09/11/2016.

For Doogar & Associates
Chartered Accountants
Reg. No.000561N


(M. S. Agarwal)
Partner
M. No. 86580

